Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Zanolimumab: Additional Phase II data

Additional data from an open-label Phase II trial in 21 patients

Read the full 110 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE